|
|
|
| Clinical effect of Pramipexole and Escitalopram in the treatment of patients with Parkinson’s disease and depression |
| YANG Xu1 ZHANG Yi1 LIU Pingping1 QU Zhanli1 HE Dongmei1 LU Taoli2 MA Ying3 |
1.Department of Neurology, Nanchong Central Hospital the Second Clinical Medical School of North Sichuan Medical College, Sichuan Province, Nanchong 637000, China;
2.Department of Neurology, Chengdu Second People’s Hospital, Sichuan Province, Chengdu 610015, China;
3.Department of Neurology, Affiliated Hospital of North Sichuan Medical College, Sichuan Province, Nanchong 637000, China |
|
|
|
Abstract Objective To explore the clinical effect of Pramipexole and Escitalopram in the treatment of Parkinson’s disease (PD) with depression. Methods A total of 120 patients with Parkinson’s disease and depression admitted to Nanchong Central Hospital in Sichuan Province from January 2018 to December 2019 were selected as the research objects. They were divided into observation group A (treated with Pramipexole), observation group B (treated with Escitalopram, 40 cases), and control group (treated with Medobar, 40 cases) by random number table method. The Hamilton depression (HAMD), unified Parkinson’s disease rating scale (UPDRS), the scores of the 39 Parkinson’s disease questionnaire (PDQ-39) and the incidence of adverse reactions of each group were analyzed. Results After treatment, the HAMD scores of the three groups were compared, and the difference was statistically significant (P ＜ 0.05). Among them, the observation group A and the observation group B were lower than the control group, and the differences were statistically significant (P ＜ 0.05). The HAMD of observation group A and observation group B were lower than before treatment, and the differences were statistically significant (P ＜ 0.05). The UPDRS and PDQ-39 scores of observation group A and observation group B were lower than those before treatment, and the differences were statistically significant (P ＜ 0.05). The UPDRS and PDQ-39 scores of observation group A and observation group B were lower than those of control group, and the differences were statistically significant (P ＜ 0.05). The total clinical effective rate of the three groups was compared, and the difference was statistically significant (P ＜ 0.05). There was no significant difference in the incidence of adverse reactions among the three groups (P ＞ 0.05). Conclusion Pramipexole and Escitalopram can effectively improve the depression of patients with Parkinson’s disease, and the therapeutic effect of Pramipexole is better than that of Escitalopram, which can significantly improve the symptoms of depression in patients and improve the quality of life of patients.
|
|
|
|
|
|
[1] Ng A，Chander RJ，Tan LC，et al. Influence of depression in mild Parkinson′s disease on longitudinal motor and cognitive function [J]. Parkinsonism Relat Disord，2015，21（9）：1056-1060.
[2] Jones JD，Butterfield LC，Song W，et al. Anxiety and depression are better correlares of parkinson′s disease quality of life than apathy [J]. J Neuropsychiatry Clin Neurosci，2015，27（3）：213-218.
[3] 胡火有，韩漫夫，肖小华，等.添加普拉克索治疗对帕金森病患者UPDRS评分及非运动症状的影响分析[J].中风与神经疾病杂志，2016，33（5）：425-428.
[4] Lemke MR，Brecht HM，Koester J，et al. Anhedonia depression and motor function in Parkinson′s disease during treatment with pramipexole [J]. Neuropsychiatry Clin Neurosci，2015，17（2）：214-220.
[5] 杜彪，杜扬，谢星星，等.文拉法辛与艾司西酞普兰治疗抑郁症的循证药物经济学评价[J].中国药房，2017，28（11）：1456-1459.
[6] 中华医学会神经病学分会帕金森病及运动障碍学组，中国医师协会神经内科医师分会帕金森病及运动障碍专业委员会.中国帕金森病的诊断标准（2016版）[J].中华神经科杂志，2016，49（4）：268-271.
[7] 中华医学会神经病学分会帕金森病及运动障碍学组.帕金森病抑郁、焦虑及精神病性障碍的诊断标准及治疗指南[J].中华神经科杂志，2013，46（1）：56-60.
[8] 韩晓英.老年慢性真实性肺疾病患者合并抑郁对临床疾病转归和生活质量的影响[J].基层医学论坛，2020，5（24）：640-641.
[9] 林晋波，蔡春生，郭琪瑜.帕金森病患者营养状态及其相关因素分析[J].实用临床医学，2020，1（21）：8-10.
[10] 彭俊霖，李昀峰，陈钢涛，等.预防性小剂量艾司西酞普兰对帕金森病患者抑郁症状及生活质量的影响[J].海峡医学，2019，10（31）：189-191.
[11] Ghaddar A，Fawaz M，Khazen G，et al. Prevalence of depression in Parkinson’s disease in a Lebanese tertiary clinic [J]. J Clin Exp Neuropsychol，2016，38（1）：51-58.
[12] 杨宇腾，牛恒，马维辉.帕金森病合并抑郁患者的临床特点及相关因素分析[J].中国卫生标准管理，2020，8（11）：45-47.
[13] 史鑫.艾司西酞普兰与西酞普兰治疗帕金森病合并抑郁的临床疗效对比[J].中国处方药，2017，4（15）：54-55.
[14] 潘晓峰，刘文娟.普拉克索联合行为疗法对早发帕金森病合并抑郁患者HAMD UPDRS评分非运动症状及生活质量的影响[J].河北医学，2019，25（8）：1240-1243.
[15] 姜立刚，李海平，李威，等.美多芭单用及联合普拉克索治疗帕金森病的疗效及安全性比较[J].中国老年学杂志，2016，36（2）：424-425.
[16] 张彬彬，候宇，娄伟.普拉克索联合多巴丝肼片治疗帕金森病的疗效及血清BDNF5-HTNE的影响[J].河北医学，2018，266（8）：1297-1301.
[17] 胡文舰，万赢，刘振国.帕金森病伴发脑小血管病的临床研究进展[J].中华神经科杂志，2018，51（3）：212-216.
[18] 刘玉祥.普拉克索联合高压氧舱治疗帕金森病合并睡眠障碍患者的临床效果[J].中国医药导报，2016，13（16）：50-53.
[19] 龙翠英，郑春玲，黄刚，等.普拉克索治疗帕金森病非运动症状的临床价值研究[J].白求恩医学杂志，2017，15（2）：197-198.
[20] 蒋雨平.普拉克索缓释片：帕金森病优化治疗的新选择[J].中国临床神经科学，2015，23（4）：439-444.
[21] 焦琳娜，章小兵，曹欣.盐酸普拉克索对帕金森病合并抑郁患者非运动症状及睡眠质量的影响[J].中国医药导报，2016，13（18）：153-156.
[22] 杨艳.艾司西酞普兰联合普拉克索片治疗帕金森病伴抑郁患者效果观察[J].吉林医学，2020，1（41）：127-129.
[23] 吴盛各，时雅辉，李铺，等.艾司西酞普兰联合普拉克索治疗帕金森抑郁的疗效观察[J].医药论坛杂志，2019， 12（40）：13-16.
[24] 白剑文，曾涛，高瑞英，等.普拉克索联合艾司西酞普兰治疗帕金森病轻度认知障碍伴发抑郁疗效的临床研究[J].国际精神病学杂志，2016，43（5）：813-816.
[25] 中华医学会神经病学分会帕金森病及运动障碍学组，中国医师协会神经内科医师分会帕金森病及运动障碍学组.帕金森病非运动症状管理专家共识（2020）[J].中华医学杂志，2020，100（27）：2084-2091. |
|
|
|
